Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 1721-1722, 2007; 10.1373/clinchem.2007.092338
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lippi, G.
Right arrow Articles by Guidi, G. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lippi, G.
Right arrow Articles by Guidi, G. C.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow General Clinical Chemistry
Right arrow Hemostasis and Thrombosis
Right arrow Drug Monitoring and Toxicology
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2007;53:1721-1722.)
© 2007 American Association for Clinical Chemistry, Inc.

Letters to the Editor

Genetic Factors for Warfarin Dose Prediction

Giuseppe Lippia, Gian Luca Salvagno and Gian Cesare Guidi

Sezione di Chimica Clinica, Dipartimento di Scienze, Morfologico-Biomediche, Università degli Studi di Verona, Verona, Italy

aAddress correspondence to this author at: Istituto di Chimica e Microscopia Clinica, Dipartimento di Scienze Morfologico-Biomediche, Università degli Studi di Verona, Ospedale Policlinico G.B. Rossi, Piazzale Scuro, 10, 37134 Verona, Italy. Fax 0039-045-8201889; e-mail ulippi@tin.it.

The first 20% of the full text of this article appears below.


To the Editor:

Warfarin, a commonly prescribed anticoagulant drug used to prevent thrombosis, has a narrow therapeutic range, and small dose variations may result in hemorrhagic or thrombotic complications. The 2 key enzymes in the metabolism of warfarin are cytochrome P450 (CYP) 2C9 (CYP2C9 gene) and the C1 subunit of the vitamin K 2,3 epoxide reductase complex (VKORC1 gene). CYP2C9 accounts for up to 85% of the metabolism of the pharmacologically more potent S-warfarin enantiomer, and VKORC1, the 2nd key enzyme in warfarin metabolism, is responsible for recycling reduced vitamin K. In their recent article, Zhu et al. (1) concluded that . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.